Similarly, in tumors with significant genetic mutations or TME dysregulation, the regulation of PD-L1 expression on both tumor cells and exosomes may vary, leading to inconsistent levels of exo-PD-L1 in the blood. This evidence concerns the gene CD274 and neoplasm.